Sarcomas | Specialty

The sarcomas/tgct condition center is a comprehensive resource for clinical news and expert insights on sarcomas/tgct. Read more at OncLive.

Dr Randall on the Multidisciplinary Foundation of Research Into Sarcoma Survivorship

December 4th 2025

R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.

Dr Randall on the Importance of Addressing Socioeconomic Disparities to Improve Sarcoma Survivorship

November 27th 2025

R. Lor Randall, MD, FACS, discusses the potential implications of research into how socioeconomic disparities and cancer biology impact long-term outcomes in pediatric sarcoma.

Dr Randall on the Goals and Methods of Prospective Research on Disparities in Sarcoma Survivorship

November 20th 2025

R. Lor Randall, MD, FACS, outlines the aims and phases of a prospective study evaluating outcome disparities in pediatric sarcoma survivorship care.

Mecbotamab Vedotin Shows Potential to Extend Survival in Treatment-Refractory Soft Tissue Sarcomas

November 20th 2025

Mecbotamab vedotin showed promising survival gains and manageable safety in treatment-refractory soft tissue sarcomas.

The OncFive: Top Oncology Articles for the Week of 11/9

November 15th 2025

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

B7-H3–Targeted ADC HN-20093 Shows Strong Efficacy, Is Still Safe at Higher Dose in R/R Sarcomas

November 14th 2025

Lu Xie, MD, discusses phase 2 efficacy and safety data with the B7-H3–targeted ADC HS-20093 in relapsed/refractory sarcomas.

FDA Grants Fast Track Designation to FOG-001 for Desmoid Tumors

November 14th 2025

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.

Dr Randall on the Need for Precision Survivorship Care in Pediatric and AYA Sarcoma

November 13th 2025

R. Lor Randall, MD, discusses the need to move beyond modest survival improvements in pediatric bone sarcoma toward equitable, precision survivorship care.

CONGRATS Trial Data of Nivolumab ± Relatlimab Highlight Clinical Value of Immunotherapy in TLS+ Soft Tissue Sarcoma

November 11th 2025

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

Precision Survivorship Platforms Are Essential for Improved, Equitable Care in Pediatric and AYA Sarcoma

November 11th 2025

R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.

The OncFive: Top Oncology Articles for the Week of 11/2

November 8th 2025

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

FDA Adds REMS Guidelines for Pexidartinib in Tenosynovial Giant Cell Tumor

November 5th 2025

The FDA has added REMS guidelines for the use of pexidartinib in tenosynovial giant cell tumor.

Dr Xie on the ARTEMIS-002 Study Investigating HS-20093 in Relapsed/Refractory Sarcomas

October 30th 2025

Lu Xie, MD, discusses the design of the phase 2 ARTEMIS-002 trial.

Dr Randall on Incorporating Ultrasound STS Surveillance Into Clinical Practice

October 30th 2025

R. Lor Randall, MD, FACS, discusses a new STS surveillance algorithm based on findings that show the comparable diagnostic utility of ultrasound and MRI.

Dr Xie on the Rationale for Investigating HS-20093 in Relapsed/Refractory Sarcomas

October 23rd 2025

Lu Xie, MD, discusses the scientific rationale and clinical development strategy for HS-20093 in the phase 2 ARTEMIS-002 trial.

Dr Randall on the Potential Role of Ultrasound in Soft Tissue Sarcoma Surveillance

October 23rd 2025

R. Lor Randall, MD, FACS, summarizes the current status of and future directions for imaging protocols for post-surgical extremity STS surveillance.

Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT

October 17th 2025

Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.

Dr Randall on the Diagnostic Accuracy and Cost Effectiveness of MRI vs Ultrasound in STS

October 16th 2025

R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.

Genetic “Trojan Horse” Selectively Kills Cancer Cells Linked to Kaposi’s Sarcoma

October 15th 2025

Targeted gene therapy kills herpesvirus-linked cancer cells, sparing healthy tissue

Abemaciclib Displays Efficacy, Tolerability in HIV-Associated and HIV-Negative Kaposi Sarcoma

October 13th 2025

Abemaciclib was safe and active for the treatment of patients with HIV-associated and -negative Kaposi sarcoma.